Abstract
Objectives
This study evaluates the value of Gd-EOB-DTPA-enhanced MRI for diagnosis and staging of non-alcoholic fatty liver disease (NAFLD) in an animal model by T1 relaxation time measurement.
Methods
Thirty-four rabbits were divided into the control group (n = 10) and NAFLD group, which was split into four groups (n = 6) with a high-fat diet for an interval of 3 weeks. A dual flip angle was performed before and at the hepatobiliary phase (HBP). T1 relaxation times of the liver parenchyma and the decrease rate (∆%) were calculated. Histological findings according to semi-quantitative scoring of steatosis, activity and fibrosis were the standard of reference.
Results
HBP and ∆% T1 relaxation time measurement showed significant differences between normal and NAFLD groups, between non-alcoholic steatohepatitis (NASH) and NAFLD without NASH (p = 0.000–0.049), between fibrosis groups (p = 0.000–0.019), but no difference between F1 and F2 (p = 0.834). The areas under the receiver operating characteristic curves (AUCs) of T1 relaxation time for HBP and ∆% were 0.86–0.93 for the selection of NASH and activity score ≥2, and 0.86–0.95 for the selection of F ≥ 1, 2, 3. No significant difference was found for diagnostic performance between HBP and ∆% T1 relaxation time.
Conclusions
HBP T1 relaxation time measurement of Gd-EOB-DTPA-enhanced MRI was useful to evaluate NAFLD according to the SAF score. HBP T1 relaxation time measurement was as accurate as ∆% T1 relaxation time.
Key Points
• Gd-EOB-DTPA-enhanced MRI could give useful information on NAFLD.
•HBP T 1 relaxation time measurement was useful for the evaluation of NAFLD.
• HBP T 1 relaxation time measurement was as accurate as ∆%.
Similar content being viewed by others
Abbreviations
- AUC:
-
area under the ROC curve
- ∆%:
-
reduction rate
- HE:
-
haematoxylin–eosin
- HBP:
-
hepatobiliary phase
- Gd-EOB-DTPA:
-
gadoxetic acid
- LSD:
-
least significant difference
- MRI:
-
magnetic resonance imaging
- MRP:
-
multidrug resistance protein
- NAFLD:
-
non-alcoholic fatty liver disease
- NASH:
-
non-alcoholic steatohepatitis
- OATP:
-
organic anion transporting polypeptide
- ROI:
-
region of interest
- ROC:
-
receiver operating characteristic
- SAF:
-
steatosis (S), activity (A) and fibrosis (F)
- SD:
-
standard deviation
- VIBE:
-
volumetric interpolated breath-hold examination
References
Brunt EM (2010) Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 7:195–203
Kleiner DE, Brunt EM, Van Natta M et al (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313–1321
Bedossa P, Poitou C, Veyrie N et al (2012) Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 56:1751–1759
Speliotes EK, Butler JL, Palmer CD, Voight BF, Hirschhorn JN (2010) PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 52:904–912
Sanyal A, Poklepovic A, Moyneur E, Barghout V (2010) Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 26:2183–2191
Ekstedt M, Franzen LE, Mathiesen UL et al (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44:865–873
Miele L, Forgione A, Gasbarrini G, Grieco A (2007) Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Transl Res 149:114–125
Dowman JK, Tomlinson JW, Newsome PN (2011) Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 33:525–540
Sofue K, Tsurusaki M, Tokue H et al (2011) Gd-EOB-DTPA-enhanced 3.0-T MR imaging: quantitative and qualitative comparison of hepatocyte-phase images obtained 10 min and 20 min after injection for the detection of liver metastases from colorectal carcinoma. Eur Radiol 21(11):2336–2343
Sun HY, Lee JM, Shin CI et al (2010) Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (<2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 45:96–103
Ichikawa T, Saito K, Yoshioka N et al (2010) Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 45:133–141
Zech CJ, Herrmann KA, Reiser MF et al (2007) MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci 6:43–52
Pascolo L, Cupelli F, Anelli PL et al (1999) Molecular mechanisms for the hepatic uptake of magnetic resonance imaging contrast agents. Biochem Biophys Res Commun 257:746–752
Tsuda N, Okada M, Murakami T (2007) Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol 42:242–247
Wu Z, Matsui O, Kitao A et al (2013) Usefulness of Gd-EOB-DTPA-enhanced MR imaging in the evaluation of simple steatosis and nonalcoholic steatohepatitis. J Magn Reson Imaging 37:1137–1143
Sonoda A, Nitta N, Ohta S et al (2011) The possibility of differentiation between nonalcoholic steatohepatitis and fatty liver in rabbits on Gd-EOB-DTPA-enhanced open-type MRI scans. Acad Radiol 18:525–529
Tsuda N, Okada M, Murakami T (2010) New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI. Eur J Radiol 73(1):137–142
Tsuda N, Matsui O (2011) Signal profile on Gd-EOB-DTPA-enhanced MR imaging in non-alcoholic steatohepatitis and liver cirrhosis induced in rats: correlation with transporter expression. Eur Radiol 21(12):2542–2550
Katsube T, Okada M, Kumano S et al (2011) Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Invest Radiol 46:277–283
Katsube T, Okada M, Kumano S et al (2012) Estimation of liver function using T2* mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. Eur J Radiol 81:1460–1464
Materne R, Smith AM, Peeters F et al (2002) Assessment of hepatic perfusion parameters with dynamic magnetic resonance imaging. Magn Reson Med 47:135–142
DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845
Motosugi U, Ichikawa T, Oguri M et al (2011) Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio index. Magn Reson Imaging 29(8):1047–1052
Watanabe H, Kanematsu M, Goshima S et al (2011) Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging–preliminary observations. Radiology 259(1):142–150
Yamada A, Hara T, Li F et al (2011) Quantitative evaluation of liver function with use of gadoxetate disodium-enhanced MR imaging. Radiology 260(3):727–733
Dahlqvist Leinhard O, Dahlström N, Kihlberg J et al (2012) Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study. Eur Radiol 22(3):642–653
Horsthuis K, Nederveen AJ, de Feiter MW et al (2009) Mapping of T1-values and Gadolinium-concentrations in MRI as indicator of disease activity in luminal Crohn’s disease: a feasibility study. J Magn Reson Imaging 29(2):488–493
Deoni SC, Rutt BK, Peters TM (2003) Rapid combined T1 and T2 mapping using gradient recalled acquisition in the steady state. Magn Reson Med 49(3):515–526
Yoshimura N, Saito K, Saguchi T et al (2013) Distinguishing hepatic hemangiomas from metastatic tumors using T1 mapping on gadoxetic-acid-enhanced MRI. Magn Reson Imaging 31(1):23–27
Fisher CD, Lickteig AJ, Augustine LM et al (2009) Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur J Pharmacol 613(1–3):119–127
Schwenzer NF, Springer F, Schraml C et al (2009) Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 51(3):433–445
Acknowledgements
The scientific guarantor of this publication is Mengsu Zeng. The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article. This study received funding from the National Science Foundation for Young Scientists of China (Grant No. 81001025). One of the authors has significant statistical expertise. Institutional review board approval was obtained. Approval from the institutional animal care committee was obtained. No study subjects or cohorts have been previously reported.
Methodology: experimental study performed at one institution.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ding, Y., Rao, SX., Meng, T. et al. Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease. Eur Radiol 24, 959–966 (2014). https://doi.org/10.1007/s00330-014-3096-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-014-3096-y